SBS 2011 Schedule, March 30th

Take the opportunity at SBS 2011 to learn about Cellecta's cancer drug target discovery services. Come visit us at booth #522, and be sure not to miss our oral presentation and tutorial on Wednesday, March 30:

11:00-11:30am

HT RNAi Screening of Anti-Cancer Targets With Pooled shRNA Libraries

Speaker: Alex Chenchik, Ph.D.

Alex Chenchik¹, Donato Tedesco¹, Kyle Bonneau¹, Mikhail Makhanov¹, Peiqing Sun², Andrei Gudkov³

¹Cellecta, Inc., Mountain View, CA; ²The Scripps Research Institute, La Jolla, CA; ³Roswell Park Cancer Institute, Buffalo, NY.

High throughput (HT) genetic screening using genome-wide pooled bar-coded lentiviral-based shRNA libraries in combination with HT sequencing has been used to identify genes modulating proliferation and survival in prostate, leukemia, and a panel of isogenic mammary epithelial cells (HMEC). Gene targets identified in these screens have been subsequently shown to lead to cell death in vitro when suppressed, and thus have potential as therapeutic targets. In addition to identifying specific single targets, the screening platform has been adapted to screen large sets of genes for synergistic combinations that generate a synthetic lethal phenotype when knocked down simultaneously. Advantages and limitations of pooled format genetic screens with genome-wide pooled shRNA libraries will be discussed.

12:30-1:25pm

Tutorial: RNAi Genetic Screening for Drug Target Discovery

Presenter: Paul Diehl, Ph.D.

Location: Osceola 5–6 (Food and beverages will be served.)

Lentiviral-based pooled shRNA libraries enable rapid and reliable identification of genes regulating most cell responses and potential drug targets. The silencing effects of shRNAs targeting thousands of genes can be assayed in a single screen using representative shRNA libraries and HT sequencing. We will describe applications of Cellecta’s RNAi screening platform with data from several cancer cell viability screens.

View the complete SBS Program here: http://www.slas.org/events

Please email info@cellecta.com with any comments.

Also in Cellecta Blog & News

Perturb-Seq Screening: Cell-by-Cell Analysis of Gene Perturbations Induced by Pooled CRISPR sgRNA Libraries

Gene Expression Profiling of Single-Cell Samples: DriverMap Targeted Expression Profiling vs SMART Technology

Single-cell expression analysis provides insights about gene expression and cell heterogeneity at the single-cell level. It enables the elucidation of intracellular gene regulatory networks and intracellular pathways that would otherwise be masked in bulk analysis (Massaia et al., 2018). The DriverMap™ Targeted Gene Expression Profiling (TXP) assay combines highly multiplexed RT-PCR amplification with the depth and precision of Next-Generation Sequencing (NGS) to quantitatively measure gene expression of up to 19,000 target genes in a single assay–even down to the single-cell level.

Comparing DNA vs. RNA Samples for Immune Repertoire Profiling

Adaptive immunity relies on B and T cells that recognize foreign antigens via hypervariable B cell and T cell receptors (BCRs and TCRs). Diversity among B cell and T cell receptors is primarily produced by V(D)J recombination, which involves the shuffling and joining of the variable (V), diversity (D), joining (J), and constant region (C) gene segments. This results in a diverse repertoire called the adaptive immune repertoire (AIR) that comprises multiple individual clonotypes (sequence) for particular receptor chains.